{"contentid": 488431, "importid": NaN, "name": "Jazz presents positive Xywav data at AAN 2021", "introduction": "Ireland-headquartered Jazz Pharmaceuticals has announced positive results from a Phase III study of Xywav (calcium, magnesium, potassium, and sodium oxybates).", "content": "<p>Ireland-headquartered Jazz Pharmaceuticals (Nasdaq: JAZZ) has announced positive results from a Phase III study of Xywav (calcium, magnesium, potassium, and sodium oxybates).</p>\n<p>The oral solution is being tested as a treatment for adults with idiopathic hypersomnia, an often debilitating sleep disorder characterized by chronic excessive daytime sleepiness.</p>\n<p>The data are being presented during a plenary session of the 2021 American Academy of Neurology (AAN) annual meeting.</p>\n<h2>Xywav development</h2>\n<p>Mindful of increasing generic competition in its core therapy area, Jazz has sought to develop and expand its portfolio of products targeting sleep disorders, securing approval in 2020 to market Xywav for catalepsy.</p>\n<p>The firm has also invested $300 million in the purchase of Cavion, a specialist in chronic and rare neurological diseases.</p>\n<p>The data Jazz is presenting at AAN will further quantify previously reported Phase III top-line results, which have already been submitted to the US regulator in a bid to broaden the label for Xywav.</p>\n<p>In the study, improvements in participants&rsquo; sleepiness were observed, following a commonly-used scale, moving from a mean of 15.7 at study entry to a mean of 6.1 at the end.</p>\n<p>Yves Dauvilliers, director of the Sleep Disorders Center at the Gui de Chauliac Hospital in Montpellier, France, said the improvements &ldquo;give hope to not only those living with idiopathic hypersomnia, but also to their families, friends and care teams.&rdquo;</p>\n<p>He added: &ldquo;If the new indication is approved by the FDA, I believe Xywav will make an immediate impact on patients living with idiopathic hypersomnia.&rdquo;</p>", "date": "2021-04-22 16:54:00", "meta_title": NaN, "meta_keywords": "Xywav, Jazz, positive, study, data, results, Phase, presents, announced, Ireland-headquartered, Pharmaceuticals, calcium, magnesium, potassium, sodium, JAZ", "meta_description": "Ireland-headquartered Jazz Pharmaceuticals has announced positive results from a Phase III study of Xywav (calcium, magnesium, potassium, and sodium oxybates).", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-22 16:54:17", "updated": "2021-04-22 17:09:36", "access": NaN, "url": "https://www.thepharmaletter.com/article/jazz-presents-positive-xywav-data-at-aan-2021", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "jazzpharma_big.jpg", "image2id": "jazzpharma_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Neurological", "topic_tag": "AAN, Conferences, Drug Trial, Research", "geography_tag": "USA", "company_tag": "Jazz Pharmaceuticals", "drug_tag": "Xywav", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-22 16:54:00"}